Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients

Hervé Avet-Loiseau, Nizar J. Bahlis, Wee Joo Chng, Tamas Masszi, Luisa Viterbo, Ludek Pour, Peter Ganly, Antonio Palumbo, Michele Cavo, Christian Langer, Andrzej Pluta, Arnon Nagler, Shaji Kumar, Dina Ben-Yehuda, S. Vincent Rajkumar, Jesus San-Miguel, Deborah Berg, Jianchang Lin, Helgi Van De Velde, Dixie Lee EsseltineAlessandra di Bacco, Philippe Moreau, Paul G. Richardson

Research output: Contribution to journalArticlepeer-review

57 Scopus citations

Fingerprint

Dive into the research topics of 'Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients'. Together they form a unique fingerprint.

Chemical Compounds

Medicine & Life Sciences